AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38241603 — intervention group
Group type: EXPERIMENTAL
Intervention: 70-gene risk score
Number of subjects: 5470
Study 38241603 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk 70-gene signature
Number of subjects: 5470
Study 38241603 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy
Number of subjects: 5470
Study 38241603 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor size and grade
Number of subjects: 5470
Study 38241643 — intervention group
Group type: EXPERIMENTAL
Intervention: 480 mg letermovir once daily orally or intravenously (240 mg with cyclosporin A)
Number of subjects: 28
Study 38241661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins or methylprednisolone
Number of subjects: 112
Study 38241661 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Number of subjects: 112
Study 38241758 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38241785 — intervention group
Group type: EXPERIMENTAL
Intervention: Active SMS intervention
Number of subjects: 61
Study 38241785 — intervention group
Group type: COMPARATOR
Intervention: Sham SMS intervention
Number of subjects: 61
Study 38242035 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support
Number of subjects: 1244
Study 38242035 — intervention group
Group type: EXPERIMENTAL
Intervention: High RDW (≥15%)
Number of subjects: 1244
Study 38242195 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV20 SC
Number of subjects: 668
Study 38242195 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV20 IM
Number of subjects: 668
Study 38242195 — intervention group
Group type: COMPARATOR
Intervention: PCV13 SC
Number of subjects: 668
Study 38242298 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model (random forest)
Number of subjects: 474
Study 38242324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir (DAAs)
Number of subjects: 496
Study 38242333 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 234
Study 38242333 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy for Depression (BATD)
Number of subjects: 234
Study 38242333 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 234
Study 38242351 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (n = 150)
Number of subjects: 300
Study 38242351 — intervention group
Group type: COMPARATOR
Intervention: Attention and social contact control (n = 150)
Number of subjects: 300
Study 38242358 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow up program, patient education on PICS and pain, psychological intervention based on Rehm's self-control model.
Number of subjects: 0
Study 38242358 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 38242358 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow up program
Number of subjects: 0
Study 38242530 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal CF-sensing PFA catheter
Number of subjects: 10
Study 38242550 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) at 90%-95% peak heart rate for 12 weeks
Number of subjects: 60
Study 38242550 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 38242575 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative circulating tumour DNA (ctDNA) detection
Number of subjects: 50
Study 38242575 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative ctDNA positivity
Number of subjects: 50
Study 38242575 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable postoperative ctDNA
Number of subjects: 50
Study 38242717 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 20 mg once daily plus pembrolizumab 200 mg every 3 weeks for 35 cycles
Number of subjects: 93
Study 38242720 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-chemo (Ipilimumab and Nivolumab combined with anthracycline-based chemotherapy)
Number of subjects: 82
Study 38242720 — intervention group
Group type: COMPARATOR
Intervention: Chemo-only (anthracycline-based chemotherapy)
Number of subjects: 82
Study 38242720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipi/nivo-only (cross-over arm)
Number of subjects: 82
Study 38242802 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative perfusion index
Number of subjects: 2534
Study 38242802 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-weighted average perfusion index
Number of subjects: 2534
Study 38243011 — intervention group
Group type: EXPERIMENTAL
Intervention: ADNEX model with CA125
Number of subjects: 894
Study 38243011 — intervention group
Group type: EXPERIMENTAL
Intervention: ADNEX model without CA125
Number of subjects: 894
Study 38243011 — intervention group
Group type: COMPARATOR
Intervention: ROMA
Number of subjects: 894
Study 38243094 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative copeptin (> 14 pmol·L)
Number of subjects: 502
Study 38243094 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative copeptin measurements
Number of subjects: 502
Study 38243094 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised cardiac risk index, body mass index, surgical risk, and preoperative hemoglobin
Number of subjects: 502
Study 38243173 — intervention group
Group type: EXPERIMENTAL
Intervention: new powdered human milk fortifier (nHMF)
Number of subjects: 0
Study 38243173 — intervention group
Group type: COMPARATOR
Intervention: commercially available human milk fortifiers (cHMF)
Number of subjects: 0
Study 38243201 — intervention group
Group type: EXPERIMENTAL
Intervention: Action-like video game (Eco-Rescue) designed to improve attentional control abilities
Number of subjects: 150
Study 38243201 — intervention group
Group type: EXPERIMENTAL
Intervention: Casual puzzle video game (Bejeweled) acting as a positive distraction tool
Number of subjects: 150
Study 38243201 — intervention group
Group type: COMPARATOR
Intervention: No-training control group
Number of subjects: 150
Study 38243214 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (brochures and brief training for oncologists)
Number of subjects: 750
Study 38243214 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 750
Study 38243223 — intervention group
Group type: EXPERIMENTAL
Intervention: Truenat platform/MTB assays with rapid communication of results
Number of subjects: 29
Study 38243223 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (routine care including on-site sputum smear microscopy and referral to off-site Xpert testing)
Number of subjects: 29
Study 38243223 — intervention group
Group type: EXPERIMENTAL
Intervention: Truenat platform/MTB assays
Number of subjects: 29
Study 38243266 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous perioperative ketamine infusion
Number of subjects: 0
Study 38243266 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ketamine in the postanesthesia care unit
Number of subjects: 0
Study 38243266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38243272 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: PAI with 100 mg bupivacaine per knee (totaling 300 mg bupivacaine for ACB and PAI)
Number of subjects: 57
Study 38243272 — intervention group
Group type: COMPARATOR
Intervention: Group B: PAI with 50 mg bupivacaine per knee (totaling 200 mg bupivacaine for ACB and PAI)
Number of subjects: 57
Study 38243272 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB combined with 100 mg bupivacaine and PAI with another 100 mg bupivacaine
Number of subjects: 57
Study 38243272 — intervention group
Group type: COMPARATOR
Intervention: ACB combined with 100 mg bupivacaine and PAI with 200 mg bupivacaine
Number of subjects: 57
Study 38243291 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted bronchoscopy
Number of subjects: 400
Study 38243291 — intervention group
Group type: COMPARATOR
Intervention: Electromagnetic navigational bronchoscopy
Number of subjects: 400
Study 38243296 — intervention group
Group type: EXPERIMENTAL
Intervention: Quabodepistat (QBS) in combination with delamanid and bedaquiline for 4 months
Number of subjects: 120
Study 38243296 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (rifampicin, isoniazid, ethambutol, and pyrazinamide) for 6 months
Number of subjects: 120
Study 38243297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal microbiota analysis using 16S metagenomics
Number of subjects: 1002
Study 38243297 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear discriminant analysis effect size (LEfSe)
Number of subjects: 1002
Study 38243297 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest (RF) methodology
Number of subjects: 1002
Study 38243297 — intervention group
Group type: COMPARATOR
Intervention: Intestinal microbiota analysis
Number of subjects: 1002
Study 38243301 — intervention group
Group type: COMPARATOR
Intervention: SOC (standard of care)
Number of subjects: 800
Study 38243301 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC + 12 weeks of NRT
Number of subjects: 800
Study 38243301 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC + 6 weeks of SMS
Number of subjects: 800
Study 38243301 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC + NRT + SMS
Number of subjects: 800
Study 38243301 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (SOC, NRT, SMS)
Number of subjects: 800
Study 38243307 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorsement of buprenorphine misinformation
Number of subjects: 409
Study 38243311 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum prophylaxis with vancomycin 1 g and gentamicin 5 mg/kg parenterally
Number of subjects: 414
Study 38243311 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylaxis with cefuroxime
Number of subjects: 414
Study 38243311 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum prophylaxis with vancomycin and gentamicin
Number of subjects: 414
Study 38243396 — intervention group
Group type: EXPERIMENTAL
Intervention: Shear-wave elastography (SWE) at 30-degree knee flexion
Number of subjects: 63
Study 38243396 — intervention group
Group type: EXPERIMENTAL
Intervention: Shear-wave elastography (SWE) measurements
Number of subjects: 63
Study 38243705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4)
Number of subjects: 638
Study 38243722 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 569
Study 38243727 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD IRT (integrated risk tool combining QRISK2 and polygenic risk score)
Number of subjects: 832
Study 38243727 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD IRT
Number of subjects: 832
Study 38243752 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy (CT) - relugolix 40 mg, oestradiol 1 mg, norethisterone acetate 0.5 mg, once daily for up to 104 weeks.
Number of subjects: 802
Study 38243752 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by relugolix CT (placebo for 24 weeks followed by relugolix CT).
Number of subjects: 802
Study 38243752 — intervention group
Group type: COMPARATOR
Intervention: Delayed relugolix CT (relugolix 40 mg monotherapy for 12 weeks, followed by relugolix CT).
Number of subjects: 802
Study 38243906 — intervention group
Group type: EXPERIMENTAL
Intervention: ANV419 administered by intravenous infusion at doses of 243 µg/kg (RP2D/MTD)
Number of subjects: 40
Study 38243998 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided axillary venous access
Number of subjects: 270
Study 38243998 — intervention group
Group type: COMPARATOR
Intervention: Standard fluoroscopic technique for axillary venous access
Number of subjects: 270
Study 38244105 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated chemoradiation (40 Gy of 3D-conformal RT in 15 fractions over 3 weeks with concurrent weekly cisplatin 40 mg/m2)
Number of subjects: 59
Study 38244105 — intervention group
Group type: COMPARATOR
Intervention: Standard chemoradiation (45 Gy in 25 fractions over 5 weeks with concurrent weekly cisplatin 40 mg/m2)
Number of subjects: 59
Study 38244105 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated chemoradiation
Number of subjects: 59
Study 38244105 — intervention group
Group type: COMPARATOR
Intervention: Standard chemoradiation
Number of subjects: 59
Study 38244145 — intervention group
Group type: EXPERIMENTAL
Intervention: After-hours robotic-assisted cholecystectomy (RAC)
Number of subjects: 505
Study 38244145 — intervention group
Group type: COMPARATOR
Intervention: Business-hours robotic-assisted cholecystectomy (RAC)
Number of subjects: 505
Study 38244179 — intervention group
Group type: EXPERIMENTAL
Intervention: RYKINDO® (Rykindo) administered biweekly (Q2W)
Number of subjects: 0
Study 38244179 — intervention group
Group type: COMPARATOR
Intervention: RISPERDAL® (Risperdal)
Number of subjects: 0
Study 38244179 — intervention group
Group type: COMPARATOR
Intervention: RISPERDAL CONSTA® (Consta; Q2W)
Number of subjects: 0
Study 38244384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy-Taking it Further (MBCT-TiF)
Number of subjects: 164
Study 38244384 — intervention group
Group type: COMPARATOR
Intervention: Ongoing Mindfulness Practice (OMP)
Number of subjects: 164
Study 38244557 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antimicrobial therapy
Number of subjects: 213
Study 38244557 — intervention group
Group type: COMPARATOR
Intervention: Intravenous standard therapy
Number of subjects: 213
Study 38244557 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral switch antimicrobial therapy
Number of subjects: 213
Study 38244708 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent training (MCT) for 6 months
Number of subjects: 104
Study 38244708 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent training (MCT) during detraining period
Number of subjects: 104
Study 38244708 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 104
Study 38244927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) administered at 10 mg/kg intravenously on days 1 and 8 of 21-day cycles
Number of subjects: 113
Study 38244927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 113
Study 38244989 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin-mineral (MVM) supplementation
Number of subjects: 573
Study 38244989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 573
Study 38245015 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-front ultrasound-guided pleural pigtail catheter thoracentesis in addition to standard pharmacological therapy
Number of subjects: 126
Study 38245015 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacological therapy only
Number of subjects: 126
Study 38245014 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed exergaming intervention for upper limb rehabilitation for 3 months
Number of subjects: 0
Study 38245113 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB Host Response (Xpert HR) blood-based assay
Number of subjects: 1499
Study 38245116 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003
Number of subjects: 20099
Study 38245116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20099
Study 38245324 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 kHz spinal cord stimulation (SCS)
Number of subjects: 0
Study 38245324 — intervention group
Group type: COMPARATOR
Intervention: Low frequency spinal cord stimulation (SCS)
Number of subjects: 0
Study 38245375 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVOY® Sepsis algorithm with active sepsis alerts
Number of subjects: 304
Study 38245375 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (silent predictions by NAVOY® Sepsis)
Number of subjects: 304
Study 38245668 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination campaign offered free of cost to high-risk patients at one public tertiary-level hospital.
Number of subjects: 0
Study 38245668 — intervention group
Group type: COMPARATOR
Intervention: No vaccination offered at the second public tertiary-level hospital.
Number of subjects: 0
Study 38245724 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus Ticagrelor for one month, followed by five months Ticagrelor monotherapy, and then Aspirin monotherapy for six months (Experimental group)
Number of subjects: 1908
Study 38245724 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus Ticagrelor for 12 months (Reference group)
Number of subjects: 1908
Study 38245730 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoelectric interface for neurorehabilitation (MINT) conditioning
Number of subjects: 9
Study 38245741 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist (NAVA)
Number of subjects: 0
Study 38245741 — intervention group
Group type: COMPARATOR
Intervention: Assist control ventilation (ACV)
Number of subjects: 0
Study 38245741 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 0
Study 38245741 — intervention group
Group type: COMPARATOR
Intervention: ACV
Number of subjects: 0
Study 38245818 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg
Number of subjects: 156
Study 38245818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 38246187 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizures during active cooling only
Number of subjects: 129
Study 38246187 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizures during and after active cooling
Number of subjects: 129
Study 38246187 — intervention group
Group type: COMPARATOR
Intervention: EEG background (worse background) at 12 h
Number of subjects: 129
Study 38246187 — intervention group
Group type: COMPARATOR
Intervention: EEG background (worse background) at 24 h
Number of subjects: 129
Study 38246187 — intervention group
Group type: EXPERIMENTAL
Intervention: Total seizure burden
Number of subjects: 129
Study 38246194 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-4157 plus pembrolizumab
Number of subjects: 157
Study 38246194 — intervention group
Group type: COMPARATOR
Intervention: pembrolizumab monotherapy
Number of subjects: 157
Study 38246235 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 461
Study 38246235 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 461
Study 38246235 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 461
Study 38246253 — intervention group
Group type: EXPERIMENTAL
Intervention: Central Sensitization Inventory (CSI) score increase by 10
Number of subjects: 0
Study 38246253 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional chronic pain comorbidity/psychological variable
Number of subjects: 0
Study 38246526 — intervention group
Group type: EXPERIMENTAL
Intervention: Licorice (100 mg GA/d)
Number of subjects: 28
Study 38246526 — intervention group
Group type: COMPARATOR
Intervention: Control product
Number of subjects: 28
Study 38246842 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination
Number of subjects: 1142
Study 38246903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical Bone Trajectory (CBT)
Number of subjects: 224
Study 38246903 — intervention group
Group type: COMPARATOR
Intervention: Traditional Trajectory (TT)
Number of subjects: 224
Study 38247010 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.05% cyclosporine A and 0.1% sodium hyaluronate
Number of subjects: 30
Study 38247190 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) oral pellets (40/10 mg) administered twice daily
Number of subjects: 514
Study 38247190 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC/3TC (60/30 mg) dispersible tablets
Number of subjects: 514
Study 38247384 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) treatment
Number of subjects: 1678
Study 38247384 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 1678
Study 38247730 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 0
Study 38247730 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 0
Study 38249329 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically detectable minimal residual disease (MRD)
Number of subjects: 269
Study 38249329 — intervention group
Group type: COMPARATOR
Intervention: Undetectable cytogenetic abnormalities (CAs)
Number of subjects: 269
Study 38249330 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab monotherapy
Number of subjects: 30
Study 38249336 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination
Number of subjects: 97
Study 38249336 — intervention group
Group type: COMPARATOR
Intervention: Recent exposure to chemotherapy
Number of subjects: 97
Study 38249336 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 outcomes over time
Number of subjects: 97
Study 38249387 — intervention group
Group type: EXPERIMENTAL
Intervention: Active break intervention group
Number of subjects: 292
Study 38249387 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically active learning intervention group
Number of subjects: 292
Study 38249387 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 292
Study 38249413 — intervention group
Group type: EXPERIMENTAL
Intervention: First COVID-19 lockdown
Number of subjects: 1089
Study 38249413 — intervention group
Group type: EXPERIMENTAL
Intervention: Second COVID-19 lockdown
Number of subjects: 1089
Study 38249413 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ASCVD and cardiovascular events
Number of subjects: 1089
Study 38249413 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 1089
Study 38249543 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin (two doses administered 1 week apart)
Number of subjects: 11
Study 38249543 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Number of subjects: 11
Study 38249982 — intervention group
Group type: EXPERIMENTAL
Intervention: MMFA-based art activities
Number of subjects: 0
Study 38249982 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38249987 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled amikacin (0.4 g twice daily, 5-7 days monthly for 3 months)
Number of subjects: 112